150 results on '"Adelstein, D J"'
Search Results
2. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction
3. Apport de l’échoendoscopie œsophagienne dans le traitement multidisciplinaire du cancer de l’œsophage
4. L’impact de l’ultrasonographie endoscopique œsophagienne sur le traitement chirurgical du cancer de l’œsophage
5. Is there a role for folate determinations in current clinical practice in the USA?
6. Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine
7. Gefitinib in definitive management of esophageal or gastroesophageal junction cancer: a retrospective analysis of two clinical trials
8. Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine
9. Head and neck: Editorial
10. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction
11. A prospective study of predictive factors for chemotherapy-induced nausea and vomiting.
12. A phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer.
13. Clinicopathologic features and treatment outcomes of patients (pts) with HER2-positive (pos) adenocarcinomas (ACA) of the esophagus (E) and gastroesophageal junction (GEJ).
14. Human papillomavirus (HPV)–related, p16 positive head and neck squamous cell carcinomas (HNSCCs) after stem cell transplantation (SCT) and solid organ transplantation (SOT).
15. Predictive value of restaging after induction concurrent chemoradiotherapy (CCRT) for locoregionally advanced (LRA) adenocarcinoma (ACA) of the esophagus and gastroesophageal junction (GEJ).
16. Functional outcomes after cisplatin (C)-based concurrent chemoradiation (CCRT) in patients (pts) with human papillomavirus (HPV)-related squamous cell carcinoma of the orophrarynx (SCCOP).
17. Multiagent concurrent chemoradiotherapy (MACCRT) and gefitinib in locoregionally advanced head and neck squamous cell cancer (HNSCC)
18. Multimodality treatment for distal esophageal (DE) and gastroesophageal junction (GEJ) adenocarcinoma (ACA) with celiac lymph node (CLN) involvement
19. Use of PET SUV for primary tumor to predict outcome in locally advanced esophageal cancer treated with trimodality therapy
20. A phase II trial of perioperative concurrent chemoradiotherapy (CCRT) and gefitinib (G) in locally advanced esophagus (E) and gastroesophageal junction (GEJ) cancer
21. Phase II trial of postoperative concurrent chemoradiotherapy (CCRT) for poor-prognosis cancer of the esophagus and gastroesophageal junction (GEJ)
22. S0216: A Southwest Oncology Group (SWOG) phase II trial of docetaxel (T), cisplatin (P), and fluorouracil (F) induction followed by accelerated fractionation/concomitant boost (AF/CB) radiotherapy (RT) and concurrent cisplatin for advanced head and neck squamous cell cancer (HNSCC)
23. Clinical predictors of larynx preservation (LP) after multiagent concurrent chemoradiotherapy (MCCRT)
24. Phase II trial of weekly docetaxel and gemcitabine as first line therapy for patients with advanced non-small cell lung cancer
25. The predictive value of baseline fluoro-deoxy-glucose positron emission tomography (FDG-PET) standardized uptake value (SUV) for overall survival in patients (pts) with locally advanced esophageal and gastroesophageal junction (GEJ) cancer
26. Do gender and race influence survival in patients with non-small cell lung cancer brain metastases? An outcomes study utilizing the RTOG RPA class stratification
27. Does positron emission tomography (PET) improve our ability to detect residual neck node (NN) disease in patients with squamous cell head and neck cancer (SCHNC) after definitive chemoradiotherapy?
28. Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesophageal junction (GEJ) cancer
29. Multimodality therapy (MMT) for locoregionally (LR) advanced cancer of the esophagus and gastroesophageal junction (E/GEJ): The impact of clinical heterogeneity
30. Does gefitinib aggravate radiation induced respiratory dysfunction?
31. Is the second primary malignancy an important competing cause of death in patients (pts) with squamous cell head and neck cancer (SCHNC)?
32. Long-term follow-up after chemoradiotherapy (CRT) and surgery in patients (pts) with stage III non-small cell lung cancer (NSCLC): Is bulky mediastinal nodal disease of prognostic importance
33. Validation of the RTOG recursive partitioning analysis (RPA) classification for small cell lung cancer-only brain metastases: A single institution experience
34. Maximizing Local Control and Organ Preservation in Stage IV Squamous Cell Head and Neck Cancer With Hyperfractionated Radiation and Concurrent Chemotherapy
35. Q: Should a patient with a brain tumor receive anticoagulation for a thromboembolic event?
36. Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study.
37. Syndrome of inappropriate secretion of antidiuretic hormone after infusional vincristine
38. Managing Three Common Oncologic Emergencies
39. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck.
40. Concurrent radiation therapy, 5-fluorouracil, and cisplatin for stage II, III, and IV, node-negative, squamous cell head and neck cancer. Results and surgical implications.
41. Simultaneous versus sequential combined technique therapy for squamous cell head and neck cancer.
42. Thromboembolic events in patients with malignant superior vena cava syndrome and the role of anticoagulation.
43. Treatment of advanced stage mycosis fungoides with bleomycin, doxorubicin, and methotrexate with topical nitrogen mustard (BAM-M).
44. High-dose cytosine arabinoside in previously treated patients with poor-prognosis non-Hodgkin's lymphoma.
45. Bone marrow morphologic changes after combination chemotherapy including VP-16.
46. Esophageal carcinoma. A six-year review of the Cleveland Veterans Administration Hospital experience.
47. Recent randomized trials of chemoradiation in the management of locally advanced head and neck cancer.
48. Treatment of head and neck cancer: the role of chemotherapy
49. The role of surgery in the management of selected patients with small-cell carcinoma of the lung.
50. Cerebellar toxicity with high-dose cytosine arabinoside.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.